Haplotype analysis in western European patients with mal de Meleda: founder effect for the W15R mutation in theSLURP1gene

2013 ◽  
Vol 168 (6) ◽  
pp. 1372-1374 ◽  
Author(s):  
R.G.L. Nellen ◽  
P.M. Steijlen ◽  
H.C. Hennies ◽  
J. Fischer ◽  
C.S. Munro ◽  
...  
Author(s):  
Hojat Shahraki ◽  
Akbar Dorgalaleh ◽  
Majid Fathi ◽  
Shadi Tabibian ◽  
Shahram Teimourian ◽  
...  

Congenital factor XIII (FXIII) deficiency is an extremely rare bleeding disorder (RBD) with estimated prevalence of one per 2 million in the general population. The disorder causes different clinical manifestations such as intracranial hemorrhage (ICH), recurrent miscarriage, umbilical cord bleeding, etc. High incidence of the disorder might be due to founder effect. To assess founder effect, haplotype analysis is an important step. For this purpose, suitable and reliable genetic markers such as microsatellites (Hum FXIIIA01 and HumFXIIIA02) and single nucleotide polymorphisms (SNP) are suggested. In the present study we tried to describe evaluation of founder effect in patients with congenital FXIII deficiency via haplotype analysis using suitable genetic markers.  


2020 ◽  
Vol 57 (7) ◽  
pp. 487-499
Author(s):  
Qing Wang ◽  
Julie Leclerc ◽  
Gaëlle Bougeard ◽  
Sylviane Olschwang ◽  
Stéphanie Vasseur ◽  
...  

BackgroundHeterozygous germline PMS2 variants are responsible for about 5% of Lynch syndrome (LS) but their prevalence is most likely underestimated because of complicated routine screening caused by highly homologous pseudogenes. Consequently, there is limited knowledge on the implication of the PMS2 gene in LS.MethodsWe report 200 PMS2 heterozygous variants identified in 195 French patients, including 112 unique variants classified as class-3/4/5.ResultsGenomic rearrangements account for 18% of alterations. The c.137G>T variant was observed in 18% of the patients, but a founder effect could not be clearly identified by haplotype analysis. Among class-4/5 variant carriers, the median age at first tumour onset was 49 years with a predominance of colorectal (80%) and endometrial (8.1%) cancers. Seven patients developed colorectal cancers before the age of 30 with the youngest at the age of 21. Only 6.2% of class-4/5 carriers had a family history fulfilling Amsterdam I/II criteria among patients with available data. Tumours from PMS2 variant carriers exhibited microsatellite instability (96%) and loss of PMS2 expression (76%), confirming the high predictive value of somatic analysis.ConclusionOur results provide further insight into the role of the PMS2 gene in LS. While PMS2 variants are mostly detected in families not fulfilling Amsterdam criteria, which supports their lower penetrance, they can nevertheless cause early-onset cancers, highlighting the variability of their penetrance.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1005-1005
Author(s):  
Roberta Russo ◽  
Maria Rosaria Esposito ◽  
Antonella Gambale ◽  
Annaelena Troiano ◽  
Maria Luisa Serra ◽  
...  

Abstract Abstract 1005 The Congenital Dyserythropoietic Anemia type II (CDA II) is an autosomal recessive disorder characterized by an impaired differentiation-proliferation pathway of the erythroid lineage. The vast majority of CDA II cases are associated with mutations in the SEC23B gene, codifying a component of the cytoplasmic coat protein II complex, involved in the anterograde transport of correctly folded protein from the endoplasmic reticulum towards the Golgi (Fromme JC et al, Trends Cell Biol 2008). To date, 86 unrelated cases from CDA II International Registry and 53 different causative mutations have been described (Schwarz K et al, Nat Gen 2009; Bianchi P et al, Hum Mut 2009; Iolascon A et al, Haematologica 2010; Fermo E et al, Blood Cells Mol Dis 2010; Russo R et al, in submission [humu-2010-0373]). This set of patients is composed of 45 cases of Italian origin, and 39 without Italian origin (WIO). Two cases are of unknown origin. Our aim is to characterize the allelic distribution of SEC23B gene mutations in Italian country, in order to define a possible founder effect for the most frequent variants. In this study we included 17 Italian and 6 WIO patients still unpublished, with an overall count of 62 Italian and 45 WIO patients, respectively. Written consent was obtained from all patients in accordance with the Declaration of Helsinki. Genomic DNA preparation, mutational search, oligonucleotide primers design and direct sequencing were performed as previously described (Iolascon A et al, Haematologica 2010). Overall we found 30 different causative mutations in Italian patients (13 missense, 8 nonsense, 4 frameshift, 4 splice site mutations and one amino acid deletion) and 32 in WIO patients (19 missense, 8 nonsense, 3 frameshift and 2 splice site mutations). The most representative variants in Italian cohort are E109K and R14W substitutions (27.2%), confirming our previous data (Iolascon A et al, Haematologica 2010). When we analyzed the allelic frequency of 10 mutations (E109K, R14W, R701C, R497C, R217X, R79X, A524V, R264X, R339X, R535X) common to both cohort, we found that R14W variant showed an higher recurrence in Italian CDA II patients when compared to WIO patients (27.2% vs 10.7%). Moreover, E109K substitution showed almost the same allelic frequency between both groups, with only a little prevalence in Italian cohort (27.2% in Italian patients vs 25.0% in those WIO). This observation lead us to investigate whether their frequencies are due to a possible mutational hot spot (i.e. arisen independently) or, perhaps, to a possible founder effect for both mutations, E109K and R14W. So, we performed an haplotype analysis in a case-control study. Here, we focused our attention on E109K mutation. Using the genotype data of CEU population from HapMap Project web site (http://hapmap.ncbi.nlm.nih.gov/) we downloaded a list of 9370 single nucleotide polymorphisms (SNPs) within a region of 1685 kb upstream, 2656 kb downstream of the SEC23B gene and throughout the gene. From this list, we selected 12 tag-SNPs covering a region of about 1.2 Mb upstream and downstream of the E109K mutation. Tag-SNPs were identified using Haploview software (Barrett JC et al, Bioinformatics 2005), with a threshold of r2 > 0.8 and with a minor allele frequency > 0.35. From 27% of patients with E109K mutation, genotyping was performed by direct sequencing on 16 unrelated patients, 14 homozygotes and 2 heterozygotes for E109K variant. As healthy controls we downloaded genotypes information of 174 unrelated Caucasian subjects (CEU population) available from HapMart. Haplotype analysis, performed using Haploview software, showed that the haplotype CATAGT (composed of 6 SNPs spanning in a 28.8 kb region upstream and downstream of the mutation) is common to the majority of E109K-patients (96.9%); instead, the same haplotype was found only in a smaller percentage (3%) in healthy controls. Additional genetics analyses are ongoing to estimate the age of E109K mutation using a (i) marker by marker approach or (ii) an intra-allelic model to assess the linkage disequilibrium across the marker set, implemented in DMLE+2.2 software. Since the R14W mutation showed an allelic frequency in Italy similar to those observed for E109K, we are testing if also R14W may occur on a common genetic background. Disclosures: No relevant conflicts of interest to declare.


2020 ◽  
Author(s):  
Yoo-Mi Kim ◽  
Jin-Ho Choi ◽  
Gu-Hwan Kim ◽  
Young Bae Sohn ◽  
Jung-Min Ko ◽  
...  

Abstract Background Gaucher disease (GD) is caused by a deficiency of β-glucocerebrosidase, encoded by GBA. Haplotype analyses previously demonstrated founder effects for particular GBA mutations in Ashkenazi Jewish and French-Canadian populations. This study aimed to investigate the clinical characteristics and mutation spectrum of GBA in Korean GD patients and to identify founder effect of GBA p.G85E in non-neuronopathic GD patients. Results The study cohort included 63 GD patients from 58 unrelated families. Among them, 18 patients from 17 families harboured the p.G85E mutation. Haplotype analysis was performed for 9 probands and their parents for whom DNA samples were available. In 58 unrelated probands, the GBA mutation p.L483P was the most common (30/116 alleles, 26%), followed by p.G85E (16%), p.F252I (13%), and p.R296Q (10%). Of the 18 patients harbouring the p.G85E mutation, their median age at diagnosis was 3.8 (range 1.2–57) years. No patients developed neurological symptoms during follow-up periods of 2.2–20.3 (median 13.9) years. The size of the shared haplotype containing GBA p.G85E was 732 kbp, leading to an estimated age of 3,075 years. Conclusion The GBA p.G85E mutation, which appears to be neuroprotective despite producing distinctive visceromegaly and skeletal symptoms, exhibited a potential founder effect in Korean GD patients.


2010 ◽  
Vol 31 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Sonia Garritano ◽  
Federica Gemignani ◽  
Edenir Inez Palmero ◽  
Magali Olivier ◽  
Ghyslaine Martel-Planche ◽  
...  

2020 ◽  
Author(s):  
Yoo-Mi Kim ◽  
Jin-Ho Choi ◽  
Gu-Hwan Kim ◽  
Young Bae Sohn ◽  
Jung-Min Ko ◽  
...  

Abstract Background Gaucher disease (GD) is caused by a deficiency of β-glucocerebrosidase, encoded by GBA. Haplotype analyses previously demonstrated founder effects for particular GBA mutations in Ashkenazi Jewish and French-Canadian populations. This study aimed to investigate the clinical characteristics and mutation spectrum of GBA in Korean GD patients and to identify founder effect of GBA p.G85E in non-neuronopathic GD patients. Results The study cohort included 62 GD patients from 58 unrelated families. Among them, 18 patients from 17 families harbored the p.G85E mutation. Haplotype analysis was performed for 9 probands and their parents for whom DNA samples were available. In 58 unrelated probands, the GBA mutation p.L483P was the most common (30/116 alleles, 26%), followed by p.G85E (16%), p.F252I (13%), and p.R296Q (9%). The median age at diagnosis of the 18 patients harboring the p.G85E mutation was 3.8 (range 1.2–57) years. No patients developed neurological symptoms during follow-up periods of 2.2–20.3 (median 13.9) years. The size of the shared haplotype containing GBA p.G85E was 732 kbp, leading to an estimated age of 3,075 years. ConclusionThe GBA p.G85E mutation, which appears to be neuroprotective despite producing distinctive visceromegaly and skeletal symptoms, exhibited a potential founder effect in Korean GD patients.


2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Mbarka Bchetnia ◽  
Nadia Laroussi ◽  
Monia Youssef ◽  
Cherine Charfeddine ◽  
Ahlem Sabrine Ben Brick ◽  
...  

Mal de Meleda (MDM) is a rare, autosomal recessive form of palmoplantar keratoderma. It is characterized by erythema and hyperkeratosis of the palms and soles that progressively extend to the dorsal surface of the hands and feet. It is caused by mutations inSLURP-1gene encoding for secreted mammalian Ly-6/uPAR-related protein 1 (SLURP-1). We performed mutational analysis by direct sequencing ofSLURP-1gene in order to identify the genetic defect in three unrelated families (families MDM-12, MDM-13, and MDM-14) variably affected with transgressive palmoplantar keratoderma. A spectrum of clinical presentations with variable features has been observed from the pronounced to the transparent hyperkeratosis. We identified the 82delT frame shift mutation in theSLURP-1gene in both families MDM-12 and MDM-13 and the missense variation p.Cys99Tyr in family MDM-14. To date, the 82delT variation is the most frequent cause of MDM in the world which is in favour of a recurrent molecular defect. The p.Cys99Tyr variation is only described in Tunisian families making evidence of founder effect mutation of likely Tunisian origin. Our patients presented with very severe to relatively mild phenotypes, including multiple keratolytic pits observed for one patient in the hyperkeratotic area which was not previously reported. The phenotypic variability may reflect the influence of additional factors on disease characteristics. This report further expands the spectrum of clinical phenotypes associated with mutations inSLURP1in the Mediterranean population.


2003 ◽  
Vol 120 (6) ◽  
pp. 967-969 ◽  
Author(s):  
Guofang Hu ◽  
Mehmet Yildirim ◽  
Vahide Baysal ◽  
Ozlem Yerebakan ◽  
Ertan Yilmaz ◽  
...  

Author(s):  
Inge A. Meijer ◽  
Nicolas Dupré ◽  
Bernard Brais ◽  
Patrick Cossette ◽  
Judith St-Onge ◽  
...  

Background:The most common cause of autosomal dominant Hereditary Spastic Paraplegia (HSP) is mutations in the SPG4 gene. We have previously identified novel SPG4 mutations in a collection of North American families including the c.G1801A mutation present in two families from Quebec. The aim of this study is to estimate the frequency of the c.G1801A mutation in the French Canadian (FC) population and to determine whether this mutation originates from a common ancestor.Methods:We collected and sequenced exon 15 in probands of 37 families. Genotypes of markers flanking the SPG4 gene were used to construct haplotypes in five families. Clinical information was reviewed by a neurologist with expertise in HSP.Results:We have identified three additional unrelated families with the c.G1801A mutation and haplotype analysis revealed that all five families share a common ancestor. The mutation is present in 7% of all our FC families and explains half of our spastin linked FC families. The phenotype associated with the c.G1801A genotype is pure HSP with bladder involvement.Conclusion:In this study we have determined that the relative frequency of the c.G1801A mutation in our FC collection is 7%, and approximately 50% in the spastin positive FC group. This mutation is the most common HSP mutation identified in this population to date and is suggestive of a founder effect in Quebec.


2021 ◽  
Vol 11 ◽  
Author(s):  
Jun Li ◽  
Sile Han ◽  
Cuiyun Zhang ◽  
Yanlin Luo ◽  
Li Wang ◽  
...  

Predisposition of germline BRCA1/2 mutations (gBRCAMUT) increases the risk of breast and ovarian cancer in females, but the mutation prevalence and spectrum are highly ethnicity-specific with different recurrent mutations being reported in different populations. Hereby, we performed hybridization-based target sequencing of BRCA1/2 in 530 ovarian cancer patients from Henan, the central region of China, followed by haplotype analysis of six short tandem repeat (STR) markers in the patients with recurrent mutations to determine their founder effect. About 28.3% (150/530) of the OC patients in our cohort harbored gBRCAMUT; of the 151 mutations, 117 in BRCA1 and 34 in BRCA2, identified in this study, BRCA1:c.5470_5477del, c.981_982del, and c.4065_4068del are the top three mutants, recurrently detected in eight, seven, and six independent patients respectively. Haplotype analysis identified a region of 0.6 MB genomic length covering BRCA1 highly conserved across all eight carriers of BRCA1:c.5470_5477del, but not c.981_982del, suggesting a consequence of founder effect. Retrospective analysis in a subgroup of serous ovarian cancer patients revealed gBRCAMUT status was not associated with the progression-free survival (PFS); instead, an expression of Ki-67% ≥50% was associated with a shorter PFS (p = 0.041). In conclusion, patients with pathogenic or likely pathogenic gBRCAMUT account for 28.3% of the OC cases from Henan, and BRCA1:c.5470_5477del, the most frequently detected mutation in Henan patients, is a founder mutation in the population.


Sign in / Sign up

Export Citation Format

Share Document